1285.4000 -18.80 (-1.44%)
NSE Sep 11, 2025 09:35 AM
Volume: 159.9K
 

ICICI Securities Limited
Q2 revenues grew 2.0% YoY to | 4911 crore (I-direct estimate: | 4564 crore) mainly due to strong growth across segments partly offset by high base effect in Q2FY20 (divestiture of certain proprietary products). US revenues grew 28.5% YoY to | 1833 crore on the back of rupee depreciation and new product launches. Domestic revenues grew 21.5% YoY to | 912 crore due to Wockhardt integration and Covid products. Europe revenues grew 35.8% YoY to | 375 crore due to new launches and currency tailwinds. PSAI segment posted a robust 19.7% YoY growth to | 851 crore. EBITDA margins...
Dr. Reddy's Laboratories Ltd. is trading above all available SMAs
More from Dr. Reddy's Laboratories Ltd.
Recommended